A narrative review on Naringin and Naringenin as a possible bioenhancer in various drug-delivery formulations.
Pradeepti GaneshVanishree SureshManoj Kumar NarasimhanSabarathinam SarveshPublished in: Therapeutic delivery (2023)
Naringenin belongs to the flavanones and is mainly found in fruits (grapefruit and oranges) and vegetables. Naringenin exhibits lipid-lowering and insulin-like characteristics and is used to treat osteoporosis, cancer and cardiovascular disorders. Their incorporation into drug formulations offers several advantages, including enhanced solubility, improved bioavailability and targeted delivery. Naringin-based formulations are beneficial in cancer, for example controlling breast and prostate cancer by inhibition of CYP19. Naringin suppresses the PI3K/AKT signalling pathway, it triggers autophagy, which effectively halts the proliferation of gastric cancer cells. Naringin and naringenin co-administration or pre-administration has enhanced the target drug's potency and produced a synergistic effect. This published study demonstrates the potential applications of Naringin and Naringenin as recognized bio-enhancers.
Keyphrases
- prostate cancer
- papillary thyroid
- drug delivery
- signaling pathway
- type diabetes
- squamous cell
- cell death
- postmenopausal women
- radical prostatectomy
- oxidative stress
- human health
- emergency department
- lymph node metastasis
- young adults
- drug induced
- bone mineral density
- endoplasmic reticulum stress
- fatty acid
- risk assessment
- climate change
- skeletal muscle
- glycemic control
- health risk
- weight loss